Veracyte
The company welcomed favorable results last week from a study comparing its test to a narrower ddPCR-based approach in patients from an ongoing interventional trial.
Top Five Articles on 360Dx Last Week: Cepheid Layoffs; Federal Spending Squeeze at Quanterix; More
Last week, readers were most interested in a story about layoffs at Cepheid that will take effect in May.
Craig-Hallum Initiates Coverage of Veracyte With Buy Rating, $45 Price Target
The investment bank views the company as a promising target with a strong track record and prospects for expansion into new, under-penetrated markets.
360Dx Top 30 Drops 9 Percent in February
Of the 30 companies on the list, 22 firms saw their share prices decline month over month, while eight companies saw their stock prices rise.
Veracyte Eyes Dropping IVD/Pharma Subsidiary in Europe As Growth Concentrates Among Clinical LDTs
Premium
Company officials lauded its core tests and shared news about launches planned for the upcoming year, including its minimal residual disease assay.
Oct 16, 2024
UBS Initiates Coverage of Veracyte With Buy Rating
Sep 3, 2024
360Dx Top 30 Ticks up 2 Percent in August
Aug 8, 2024